Group 1 - Nova Ltd. (NVMI) closed at $190.17, with a 10% gain over the past four weeks, and a mean price target of $255.83 suggests a 34.5% upside potential [1] - The mean estimate includes six short-term price targets with a standard deviation of $19.60, indicating variability among analysts; the lowest estimate is $235 (23.6% increase), while the highest is $280 (47.2% increase) [2] - Analysts show strong agreement on NVMI's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for NVMI has increased by 3.6% due to two upward revisions in earnings estimates over the last 30 days, with no negative revisions [12] - NVMI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [13]

Core Viewpoint - EverQuote (EVER) shares have increased by 12.7% in the past four weeks, closing at $23.99, with a potential upside of 42.4% based on Wall Street analysts' mean price target of $34.17 [1] Price Targets and Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $2.79, indicating variability among analysts; the lowest estimate of $30 suggests a 25.1% increase, while the highest target of $38 indicates a potential surge of 58.4% [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates - Analysts are optimistic about EverQuote's earnings prospects, as indicated by a positive trend in earnings estimate revisions; the Zacks Consensus Estimate for the current year has risen by 7.4% over the past month, with four estimates increasing and no negative revisions [11][12] - The company holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, which further supports the potential upside for the stock [13]

Group 1 - Aris Mining Corporation (ARMN) closed at $5.73, with a 5.3% gain over the past four weeks, and a mean price target of $8.29 indicating a 44.7% upside potential [1] - The average price targets range from a low of $7.02 to a high of $10.08, with a standard deviation of $1.40, suggesting a 22.5% increase at the lowest estimate and a 75.9% upside at the highest [2] - Analysts show strong agreement on ARMN's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for ARMN's current year earnings has increased by 20.5% over the last 30 days, with two estimates moving higher and no negative revisions [12] - ARMN holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13]

Group 1 - Zoetis (ZTS) closed at $160.35, with a 7.9% gain over the past four weeks, and a mean price target of $202.33 indicating a 26.2% upside potential [1] - The average of 15 short-term price targets ranges from a low of $165 to a high of $244, with a standard deviation of $23.91, suggesting variability in analyst estimates [2] - Analysts show strong agreement on ZTS's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for ZTS has increased by 2.9% due to eight upward revisions and one downward revision in earnings estimates over the last 30 days [12] - ZTS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] - While price targets should not be the sole basis for investment decisions, the direction implied by them can serve as a useful guide [10][13]

Core Viewpoint - Zymeworks Inc. (ZYME) shows significant potential for upside, with a mean price target of $21.35 indicating an 83.9% increase from the current price of $11.61 [1] Price Targets and Analyst Consensus - The average of 10 short-term price targets ranges from a low of $12 to a high of $30, with a standard deviation of $7.45, suggesting variability in analyst estimates [2] - The lowest estimate indicates a 3.4% increase, while the highest suggests a 158.4% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts show strong agreement in revising ZYME's earnings estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 1.6%, with two estimates moving higher and no negative revisions [12] - ZYME holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on price targets for investment decisions may not be wise, as analysts' ability to set unbiased targets has been questioned [3][7] - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated estimates [8] - While price targets should not be ignored, they should be approached with skepticism [10]

Group 1 - ClearPoint Neuro, Inc. (CLPT) shares have increased by 18.2% over the past four weeks, closing at $13.64, with a mean price target of $27.67 indicating a potential upside of 102.9% [1] - The average price targets range from a low of $25 to a high of $30, with a standard deviation of $2.52, suggesting a potential increase of 83.3% to 119.9% from the current price level [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements, indicating a positive outlook for CLPT [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 0.8% over the last 30 days, with one estimate moving higher and no negative revisions [12] - CLPT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [13] - While price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movements [10][13]

Shares of Intapp (INTA) have gained 7.3% over the past four weeks to close the last trading session at $56.31, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $71 indicates a potential upside of 26.1%.The mean estimate comprises eight short-term price targets with a standard deviation of $7.95. While the lowest estimate of $60 indicates a 6.6% increase from the current price lev ...

Group 1 - Concentra Group (CON) closed at $21.40, with a 5.5% gain over the past four weeks, and a mean price target of $28 suggests a 30.8% upside potential [1] - The average price targets range from $25 to $30, with a standard deviation of $1.85, indicating a low variability among analysts' estimates [2] - Analysts are optimistic about CON's earnings prospects, with a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 1.5% over the past month, with three estimates revised higher and no negative revisions [12] - CON holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does suggest a positive direction for price movement [13]

Copa Holdings (CPA) closed the last trading session at $100.68, gaining 19% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $150.45 indicates a 49.4% upside potential.The mean estimate comprises 11 short-term price targets with a standard deviation of $20.25. While the lowest estimate of $120 indicates a 19.2% increase from the current price level, the most optimistic analyst expec ...

Shares of Immunome, Inc. (IMNM) have gained 19.7% over the past four weeks to close the last trading session at $7.43, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $26 indicates a potential upside of 249.9%.The mean estimate comprises eight short-term price targets with a standard deviation of $6.26. While the lowest estimate of $20 indicates a 169.2% increase from the curren ...